|
3.1.1 Tabac - e-cigs
|
|
|
AACR Presents E-cigarette Webinar to Educate the Public [AACR]
|
|
|
|
|
|
In
recognition of the U.S Food and Drug Administration’s (FDA) ban on
e-cigarette sales to youth in effect this past month, the American
Association for Cancer Research (AACR) Tobacco and Cancer Subcommittee
has released a new webinar, “E-cigarettes: Research, Public Health
Concerns and Opportunities, and Regulations,” featuring key experts that
will present current research on and the public health impact of
e-cigarettes.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup [Xconomy]
|
|
|
|
|
|
Fortis
is licensing the technology behind the drug program from the University
of California, San Francisco, where it was developed in the lab of Bin
Liu. Liu has identified a protein on the surface of tumor cells that the
cells use to take in nutrients. Fortis declined to divulge more details
about the target, but said Liu has submitted a paper on the topic to a
scientific journal.
|
|
|
|
|
|
|
CICON16: Corrupted by Cancer [CRI]
|
|
|
|
|
|
As
the third session here at #CICON16 can attest, we now recognize that if
we’re going to beat cancer, we’re going to have to tackle the tumor
microenvironment along with it. f
|
|
|
|
|
|
|
|
CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints [CRI]
|
|
|
|
|
|
The
second session here at the International Cancer Immunotherapy
Conference, taking place in New York City this week, discussed how
current checkpoints fail, and explored the potential of other
checkpoints that are being targeted to improve patient responses.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
Bristol-Myers And Nektar Cast Wide Net In Quest To Find The Right Immunotherapy Combo [Forbes]
|
|
|
|
|
|
If
a combo works, was it more because of drug A, drug B or something else?
If it fails, is it because the drugs don’t work well together, or
because they are being dosed in the wrong concentrations or wrong
sequence? Will two potent drugs together cause too much toxicity? Can
companies can play well together in the sandbox? What about the cost of
two drugs versus one? The list of challenges goes on.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [NICE]
|
|
|
|
|
|
Radium‑223
dichloride is recommended as an option for treating hormone-relapsed
prostate cancer, symptomatic bone metastases and no known visceral
metastases in adults, only if: - they have already had docetaxel or - docetaxel is contraindicated or is not suitable for them. The
drug is only recommended if the company provides radium‑223 dichloride
with the discount agreed in the patient access scheme.
|
|
|
|
|
|
|
Talimogene laherparepvec for treating unresectable metastatic melanoma [NICE]
|
|
|
|
|
|
Talimogene
laherparepvec is recommended, in adults, as an option for treating
unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or
IVM1a) melanoma that has not spread to bone, brain, lung or other
internal organs, only if: - treatment with systemically administered immunotherapies is not suitable and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.
|
|
|
|
|
|
|
|
Furor Over Drug Prices Puts Patient Advocacy Groups in Bind [NY Times]
|
|
|
|
|
|
“It
is a conflict of interest, because the interests of the pharmaceutical
industry, from whom they are getting support, may be different from the
interests of the patients,” said Dr. Michael Carome, the director of the
Health Research Group at Public Citizen, a consumer advocacy group.
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
6.1 Observation
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.7.3 DMP
|
|
|